Russell Brewer, DrPH, a research associate professor at University of Chicago Medicine, discusses the lessons from both the HIV epidemic and the COVID-19 pandemic in regard to how health systems can more effectively address health care disparities in BIPOC communities.
Russell Brewer, DrPH, a research associate professor at University of Chicago Medicine, and P.J. Moton-Poole, a senior manager at ViiV Healthcare, discuss the expansion of the accelerate initiative, which funds projects that support the health and wellbeing of Black same-gender-loving men throughout the United States.
The APhA and the CDC announced that they have entered into a collaborative agreement focused on supporting the role of pharmacists in building the public’s confidence in COVID-19 vaccines.
Daily national surveys by Carnegie Mellon University (CMU) show that although COVID-19 vaccine uptake has increased, the proportion of vaccine-hesitant adults has remained unchanged.
In a clinical trial of idecabtagene vicleucel in multiple myeloma, the overall response rate for the efficacy evaluable population was 72%, and 28% of participants achieved a stringent complete response.
Investigators may have found a way to locate chemicals capable of suppressing HIV into its dormant state.
Through investigating a type of toxin released by the most dangerous strains of C. diff, researchers now have a map for developing drugs that can block the toxin and prevent the bacteria from entering human cells.
The pharmacy community has stepped up mightily to ensure this massive health care effort is successful.
Mitchell Horwitz, MD, principal investigator and professor of medicine at the Duke Cancer Institute, discusses the results of a phase 3 study of omidubicel, which treats patients with hematologic malignancies in need of a bone marrow.
Researchers found no evidence that protection against COVID-19 reinfection declined within a 6-month follow-up period.
In addition to cardiotoxicity from cancer-related treatments, the researchers noted that obesity, cancer, and cardiovascular disease share some common risk factors.
Digital health products and solutions expand ways to guide prevention and treatment.
Caroline Carney, MD, MSc, FAPM, CPHQ, CMO of Magellan Health, discusses how pharmacists and other medical professionals can boost their brain health and keep a positive mindset while working during the pandemic.
Trust between a physician and pharmacist is essential to the overall quality of patient-centered care.
The plot clinical trial included 40 men and is believed to be the first published study to use progesterone to treat male COVID-19 patients whose lung functions have been compromised by the virus.
Farah Towfic, PharmD, MBA, director, CEO operations at US Pharmacopeia (USP), discusses USP’s release of an updated version of its COVID-19 Vaccine Handling Toolkit in response to feedback from independent pharmacies to mass vaccination clinics.
The COVID-19 pandemic significantly impacted pharmacy practice due to its role in supporting overwhelmed physicians, nurses, and other health care professionals who faced some of the immediate challenges of the crisis.
A new study published in The American Journal of Clinical Nutrition found that for colorectal cancer survivors, maintaining a stable body weight may hide a loss of muscle and the development of fatty deposits in their muscles, which resulted in a 40% higher risk of premature death.
Technology is essential, but not all solutions meet every goal or offer the same capabilities.
The FDA has approved the submission of a supplemental new drug application (sNDA) that expands the use of bupivacaine liposome injectable suspension to include patients aged 6 years and older for single-dose infiltration as a postsurgical local analgesia.
More than ever, confidence in objective, science-based data about therapeutics, such as the COVID-19 vaccine and other health care services, is a shared imperative across the pharmaceutical industry, health care communities, and the American public.
This vaccine rollout has become even more crucial for the US health care system, as new mutations of the coronavirus continue to emerge.
New results show that non-Hispanic Black patients with COVID-19 and type 1 diabetes have an additional risk of diabetic ketoacidosis beyond the risk of having diabetes or being of minority status.
Results from a phase 3 trial investigating the programmed cell death protein 1 inhibitor cemiplimab monotherapy compared to chemotherapy showed an overall survival benefit among patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
Electricity may slow the speed at which breast cancer cells spread through the body, and in some cases may stop them entirely, according to a new study published in Bioelectricity.
Following a review of the latest interim data released by AstraZeneca on its US phase 3 clinical trial assessing the 2-dose AZD1222 COVID-19 vaccine, the Data and Safety Monitoring Board (DSMB) expressed concern at the inclusion of what may have been outdated data.
Phase 3 clinical testing of a plant-derived COVID-19 vaccine candidate in combination with a pandemic adjuvant commenced following approval to proceed with participant enrollment from regulatory authorities in both Canada and the United States.
Investigators found a statistically significant improvement in both overall survival and progression-free survival for patients who received pembrolizumab with chemotherapy.
Low doses of propylparaben–a chemical preservative found in food, drugs, and cosmetics–can alter pregnancy-related changes in the breast in ways that may lessen the protection against breast cancer normally conveyed by pregnancy hormones.
The IGCS Mentorship and Training Program seeks to provide training and education to regions without formal training programs in gynecologic oncology.
